Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary

The preceding platinum-based combination chemotherapy could possibly reduce tumor masses, allowing for adequate surgical debulking in advanced ovarian cancer. In this study, a total of 18 patients with peritoneal carcinomatosis of the ovary were evaluated between 1996 and 2003. All patients underwent open biopsy for the histopathologic confirmation of ovarian tumor. Forty-one percent of the patients (8/18) were administered six cycles of carboplatin/cyclophosphamide (CP) and the rest were administered six cycles of paclitaxel/carboplatin (TP) as a neoadjuvant chemotherapy (10/18). After six cycles of chemotherapy metastases to the peritoneum, Douglas' pouch, diaphragm, and liver serosa were higher in the CP group than the TP group (p < 0.05). All patients also had a better performance status (WHO performance status 0 or 1), but no statistical difference was observed between either group (p > 0.05). Optimal debulking surgery rates were significantly higher in the TP group (p < 0.05). In conclusion, we suggest paclitaxel/carboplatin in peritoneal carcinomatosis of the ovary as a neoadjuvant chemotherapy. However, large prospective, randomized studies should be performed in patients with peritoneal carcinomatosis of the ovary.

Peritoneal carcinomatosis; Ovary, Paclitaxel; Carboplatin; Cyclophosphamide; Debulking surgery

[1] Hacker N.F., Berek J.S., Lagasse L.D., Neiberg R.K., Elashoff R.M.: "Primary cytoreductive surgery for epithelial over cancer". Obstet. Gynecol., 1983, 61, 413.

[2] Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., Thiel R.P.: "Neoadjuvant chemotherapy for advanced cancer: Long term survival". Gynecol. Oneal., 1999, 72, 93,

[3] Potter M.E., Partridge E.E., Hatch K.D. et al.: "Primary surgical therapy of ovarian cancer: how much and when". Gynecol. Oneal., 1991, 40, 195.

[4] Wills J., Blijham G., Naus A. et al.: "Primary or delayed debulking surgery and chemotherapy consists of cisplatin, doxorubicin and cyclophosphamide in Stage III-IV epithelial ovarian carcinoma". J. Clin. Oneal., 1986, 4, 1068.

[5] Jacob J.H., Gershenson D.M., Morris M. et al.: "Neadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol. Oneal., 1991, 42, 146.

[6] Ozols R.F., Young R.C.: "Chemotherapy of ovarian cancer". Semin. Oneal., 1991, 18, 222.

[7] Pazdur R., KudelkaA.P., Kavanagh J.J. et al.: "The taxoids: paclitaxel (Taxol) and docataxel (Taxotere)". Cancer Treat. Rev., 1993, 19, 351.

[8] Lawton F.G., Redman C.W., Luesley D.M., Chan K.K., Blacklegde G.: "Neadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer". Obstet. Gynecol., 1989, 73, 61.

[9] Kay1ki,10glu F., Kose M.F., Boran N., Gahskan E., Tulunay G.: "Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma". Int. J. Gynecol. Cancer, 2001, 11, 466.

[10] Chan Y.M., Ng T.Y., Ngan H.Y., Wong L.C.: "Quality of life m women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study". Gynecol. Oneal., 2003, 88, 9.

[11] Schwartz P.E.: "Neoadjuvant chemotherapy for the management of ovarian cancer". Best. Pract. Res. Clin. Obstet. Gynaecol., 2002, 16, 585.

[12] Camci C., Balat O.: "Neoadjuvant chemotherapy in ovarian cancer". Eur. J. Gynaec. Oneal., 2002, 5, 437.